This one-day conference will include a mixture of plenary sessions, oral presentations and posters and will bring together leading international experts, clinicians, patient partners and early career researchers to engage with the latest advances in the field of PROMs research and implementation.
Detailed programme now available to download (PDF, 993Kb).
Plenary Speakers
We are pleased to confirm the following Plenary Speakers, Dr Daniel O'Connor, MHRA, Dr Tessa Richards, BMJ and Dr Kirstie Haywood, Warwick University.
Dr Daniel O'Connor
Daniel is a Leicester medical graduate with a background in cancer research, histopathology and oncology. His PhD in the field of tumour suppressor genes was awarded from Imperial College London and he holds an MSc in Oncology from the Institute of Cancer Research. He completed higher medical training in the UK in Pharmaceutical Medicine.
He joined the Medicines and Healthcare products Regulatory Agency (MHRA) as a Medical Assessor in 2006 from a clinical lecturer post at UCL/UCH/Ludwig Institute for Cancer Research. He works in the licensing division of the MHRA. He is the UK representative on the Committee for Orphan Medicinal Products (COMP), COMP representative on the EMA’s Scientific Advice Working Party (SAWP) and the Patient and Consumer Working Party (PCWP), and observer on the EMA’s Oncology Working Party. He is editor author of the first edition Oxford Specialist Handbook of Pharmaceutical Medicine and he is on the editorial board of the journal Expert Opinion on Orphan Drugs.
Dr Tessa Richards
Dr Tessa Richards is a senior editor at the BMJ and leads the BMJs patient partnership initiative. She worked as a general physician, rheumatologist and a GP before joining the BMJ editorial staff. Here she has led the journals GP, Education and Analysis sections, and established the Overdiagnosis/Too Much Medicine series , one on High Integrity Health. She is a member of the Royal College of Physicians, a BMJ columnist and writes regularly on patient perspectives. Series she has edited include ones on Partnering with Patients, and Patient Centred Care. She lives with stage IV cancer and two long term conditions , and is a carer for close family members with rheumatoid arthritis, dementia, and blindness.
Dr Kirstie Haywood
Kirstie leads the Patient Reported Outcomes (PRO) Research programme at Warwick Medical School. Her research interests include health-related quality of life (HRQoL), measurement science and patient-reported outcomes research in clinical practice, research and health policy. The work programme covers a wide range of conditions, populations and settings including long-term conditions (e.g., a range of musculoskeletal/rheumatological conditions, chronic fatigue), recovery from episodes of ill-health or injury (e.g., cardiac arrest, traumatic hip fracture); using / evaluating / developing PRO measures (PROMs) for use in research, clinical practice, disease registries and audit (e.g., maternity; exercise adherence; axial spondyloarthropathies); and developing approaches to effective patient and public involvement (PPI) in HRQoL and PRO research.
Recent work has included the development of Core Outcome Sets (COS) for cardiac arrest (COSCA), headache (COSH), and fragility hip fracture (WHiTE). The International COSCA initiative is endorsed by both the European Resuscitation Council (ERC) and the International Liaison Committee on Resuscitation (ILCOR). The WHiTE COS has been incorporated into England’s Hip Fracture Audit. She has contributed to the European Resuscitation Registry for Cardiac Arrests (EuReCa) stakeholder group, raising the importance of capturing the voice of survivors. She was an invited member of the ERC 2015 Resuscitation Guidelines writing group (Ethics of Resuscitation; European Survey of Resuscitation practice) and is a member of the American Heart Association (AHA) writing group tasked with developing of a ‘Statement of Survival after Cardiac Arrest’. Kirstie was an expert member of England’s DoH PROM Stakeholder Reference Group (2009-2013) and a European working group contributing to a policy debate on the role of PROs in healthcare (‘The Value of Health: Healthcare Outcomes as Drivers for Sustainable Health Systems’ (FIPRA funded)). Until recently, Kirstie co-chaired the Clinical Practice Special Interest Group (SIG) of the International Society of Quality of Life research (ISOQOL). She is a founding member and co-chair of the ISOQOL Patient Engagement SIG and member of the Trials Taskforce and working group.
Programme Overview
| 09:30 |
Registration and refreshments |
| 10:00 |
Welcome from Professor Melanie Calvert and Gary Price |
| 10:15 |
Plenary Session 1
Dr Dan O'Connor, MHRA, PROs from the regulatory perspective
Dr Tessa Richards, BMJ |
| 10:45 |
Parallel session 1 |
| |
Great Hall
Minimising PRO waste |
WG05
PROS in chronic disease/different settings |
WG12
Cutting edge methods |
| 11:45 |
Refreshments Poster Viewing |
| 12:00 |
Parallel session 2 |
| |
Great Hall
Pushing boundaries |
WG05
Economic evaluation |
WG12
Digital Capture of PROs |
| 13:00 |
Lunch and Poster Viewing |
| 14:00 |
Parallel session 3 |
| |
Great Hall
Digital Capture of PROs |
WG05
Cutting edge methods |
WG12
PROs in chronic disease/different settings |
| 15:00 |
Refreshments and Poster Viewing |
| 15:30 |
Plenary 2
Dr Kirstie Haywood, Warwick Medical School |
| 16:00 |
General discussion |
|
|
| 16:30 |
Close |
|
|
| Endorsed by the International Society for Quality of Life Research |
 |
Please be aware that photographs will be taken at this event for promotional use. If you have any concerns about this please let the event organiser know.